Status:
TERMINATED
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Lead Sponsor:
Craig L Slingluff, Jr
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Fallopian Tube Cancer
Ovarian Cancer
Eligibility:
FEMALE
18-120 years
Phase:
PHASE2
Brief Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways ...
Detailed Description
OBJECTIVES: * Determine the immunogenicity of vaccine therapy comprising synthetic ovarian cancer-associated peptides administered with a synthetic tetanus toxoid helper peptide emulsified in Montani...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer
- Stage III or IV disease
- HLA-A1, -A2, and/or -A3 positive
- Must have at least 1 undissected axillary or inguinal lymph node basin
- No recurrent disease
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Hemoglobin ≥ 8.0 g/dL
- WBC \> 3,000/mm\^3
- Absolute neutrophil count \> 1,500/mm\^3
- Hemoglobin A1c \< 7%
- AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- Bilirubin ≤ 2.5 times ULN
- Creatinine ≤ 1.5 times ULN
- HIV negative
- Hepatitis C negative
- No known or suspected allergies to any component of the study vaccine
- No other concurrent malignancy (except for nonmelanoma skin cancer) unless the patient was curatively treated and has been disease free for ≥ 5 years
- No active serious infection
- No autoimmune disorder with visceral involvement
- No prior or active autoimmune disorders requiring cytotoxic or immunosuppressive therapy
- The following immunologic conditions are allowed:
- Laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody titer) without symptoms
- Clinical evidence of vitiligo
- Other forms of depigmenting illness
- Mild arthritis requiring NSAIDs
- No New York Heart Association class III or IV heart disease
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No medical contraindication or potential problem that would preclude study compliance
- PRIOR CONCURRENT THERAPY:
- At least 2 weeks since prior and no other concurrent chemotherapy, radiotherapy, or immunotherapy (e.g., interferons, tumor necrosis factor, interleukins, or monoclonal antibodies)
- More than 4 weeks since prior and no other concurrent investigational agents
- More than 4 weeks since prior and no concurrent allergy desensitization injections
- More than 4 weeks since prior and no concurrent oral or parenteral systemic corticosteroids
- No prior or concurrent inhaled corticosteroids (e.g., fluticasone and salmetrol, fluticasone, or triamcinolone acetonide)
- Prior or concurrent topical corticosteroids allowed
- No prior vaccination with MAGE-A1:161-169, FBP:1901-199, Her-2/neu:369-377, MAGE-A1:96-104, or Her-2/neu:754-762
- More than 4 weeks since prior and no concurrent growth factors (e.g., epoetin alfa, darbepoetin alfa, or pegfilgrastim)
- No concurrent treatment for recurrent disease
- No concurrent nitrosoureas
- No concurrent illegal drug use
- Concurrent nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines, and chronic medications, unless excluded, are allowed
- Short-term therapy for acute conditions not specifically related to ovarian cancer is allowed
Exclusion
Key Trial Info
Start Date :
April 13 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 7 2008
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00373217
Start Date
April 13 2006
End Date
February 7 2008
Last Update
September 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Virginia Cancer Center
Charlottesville, Virginia, United States, 22908